Hematologic Oncology

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses the standard of care for transplant eligible patients with multiple myeloma.

Eli Lilly and Company has announced that it will acquire the biopharmaceutical company Loxo Oncology for $235 per share in cash or an estimated $8 billion.

When it works, immunotherapy can dramatically outperform standard of care—for some cancer types, in ways thought unattainable a decade ago.

Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement with Celgene Corporation under which BMS will acquire Celgene in a cash and stock transaction with an equity value of about $74 billion.

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.

The FDA has approved dasatinib tablets in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Yana Pikman, MD, a physician in the Cancer and Blood Disorders Center at Dana-Farber Cancer Institute and instructor of pediatrics at Harvard Medical School, discusses a trial attempting to match pediatric patients with more precise therapy for acute leukemia.

The FDA has approved ravulizumab-cwvz as an injection treatment of adult patients with paroxysmal nocturnal hemoglobinuria, a rare blood disorder that leads to hemolysis.

Michael Andreeff, MD, PhD, chair of genetics, professor of medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of venetoclax in acute myeloid leukemia.

The FDA has approved tagraxofusp-erzs infusion for the treatment of adult and pediatric patients, aged ≥2 years, with blastic plasmacytoid dendritic cell neoplasm.

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses cancer proliferation in multiple myeloma.

Ajai Chari, MD, associate professor of Medicine, Hematology and Medical Oncology, at Mount Sinai Hospital, discusses the use of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd) for relapsed patients with multiple myeloma.

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses the knowledge deficit in multiple myeloma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with CD30+ stage IV Hodgkin lymphoma.

Almost half of adult patients with previously treated chronic immune thrombocytopenia achieved major responses with the SYK inhibitor fostamatinib (Tavalisse).

Farhad Ravandi, MBBS, professor of medicine, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses targeting CD33 in patients with relapsed/refractory acute myeloid leukemia.

Nonpediatric young adults with stage III/IV Hodgkin lymphoma had significantly better progression-free survival when treated with brentuximab vedotin and conventional chemotherapy compared with standard therapy.

A growing understanding about the underlying biology of myelofibrosis has helped improve the diagnosis and treatment of the disease during the past decade and is paving the way for further advancements.

Data from 2 early-stage trials of bispecific T-cell engager antibody constructs in relapsed/refractory hematologic malignancies demonstrated antitumor activity and early evidence of tolerability.

The combination of nivolumab and azacitidine demonstrated favorable responses and overall survival in patients with relapsed/refractory acute myeloid leukemia.

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, Perelman School of Medicine, discusses the promise of CAR T cells in the treatment of pediatric leukemia.

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses minimal residual disease (MRD) status in multiple myeloma.

A newly discovered recurrent mutation in the B-cell leukemia/lymphoma 2 protein mediates clinical resistance to venetoclax in patients with chronic lymphocytic leukemia.

Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.